# Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome

> **NCT00003961** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases

## Interventions

- **BIOLOGICAL:** sargramostim

## Key facts

- **NCT ID:** NCT00003961
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** — (—)
- **Last updated:** 2014-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003961, "Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00003961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*